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Cell and gene therapy clinical trials have been conducted
for various indications such as cancer, cardiovascular dis-
eases and autoimmune disorders for more than 20 years.
The increased understanding of immune function, cancer
biology, and stem cell biology have dramatically accelerated
the development of technology for cell and gene therapy in
these areas. Supported by some successful clinical results,
the development of many potential new technologies has
produced an explosion of therapeutic pursuits in the clinic.
The new technologies have produced significant challenges
in the clinical translation space, including the need to
develop innovative clinical trial designs, to accelerate devel-
opment of therapies by minimizing the number of patients
required to evaluate safety and efficacy; to develop and
incorporate methods to capture important biologic effects
of cell and/or gene based therapies in patients; and to dis-
sect the impact of therapeutic combinations. Furthermore,
the increasingly personalized flavor of cell and gene thera-
pies has produced an ever-greater need for developing reli-
able biomarkers for selecting patients and measuring
biologic effects of therapy. Finally, regulatory agencies have
recognized the need for modifying acceptable evaluation
metrics to respond to the increasing complexity in clinical
design and interventions. Yet, despite significant advance-
ment in the field, progress remains slow relative to discov-
ery and the need of speeding up clinical application of
basic science discoveries is still unmet. Indeed, the rapid
advancement of therapeutic technologies in the laboratory;
the plethora of biomarker candidates; and the recent inno-
vations in clinical science concerning trial design, contrast
with the slow development process from conception of an
idea till proof of concept in the clinic. Typically, clinical
trials of this nature take several years to develop, imple-
ment, complete and report. This creates a significant gap
of knowledge in the field, as clinical innovation takes sev-
eral years to be communicated.
The incessantly evolving field of cell and gene therapy
requires early rapid and extensive communication to ensure
continuing progress. The goal of JTM ‘Clinical Translation
Section’ is to provide a new space for the rapid communica-
tion of innovative early phase clinical trials, where novel
scientific ideas are translated to the clinic, at the time of
initiation of a clinical study. These include investigator-
initiated as well as industry-sponsored clinical trials, which
have completed the regulatory process and are about to
start accruing patients. No clinical results are required.
These “white papers” review the background, rationale, clin-
ical design and approach, translational endpoints and
expected outcomes of a new clinical trial in a scholarly man-
ner, and provide the opportunity to investigators to share
their views and clinical translation efforts with a wide audi-
ence at an early stage, which could benefit greatly other
investigators in the field. Such therapies will target a range
of diseases including cancer, cardiovascular diseases, auto-
immune disorders or other common or rare diseases where
cell-based, gene-based, biological or otherwise targeted ther-
apy is applied. A broad-based and multidisciplinary editorial
board stemming from academia, biotech and pharma with
expertise in cancer immunotherapy; cellular manufacturing;
gene therapy; stem cells; regenerative medicine; cardiovascu-
lar medicine; and autoimmunity will evaluate manuscripts.
Accepted manuscripts will be distinguished for the novelty
in approach, design or clinical indication of the study and
unique ability to translate laboratory concepts from the
bench to the bedside. Lastly, this section will also provide a
platform for earlier academic recognition of the significant
efforts of translational clinical investigators whose careers
primarily depend on the execution of clinical trials.
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